NEW YORK (GenomeWeb News) – Life Technologies officials said this week that the company has formed a licensing team that will focus on offsetting declining royalty revenues for its PCR-related intellectual property and other IP.

During a conference call to discuss the company's third-quarter financial results, Life Tech Chairman and CEO Greg Lucier said that the company has assembled a team of the "best licensing people" from its Applied Biosystems and Invitrogen businesses.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.